ScreenerHero

CRMDCorMedix Inc.

NAS · US · Healthcare · Biotechnology · cormedix.com
8.200USD-3.76%Mkt Cap: 639.14M $P/E: 3.76

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an an…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap639.14M $
Enterprise Value532.24M $
Revenue (TTM)462.25M $
Gross Profit275.75M $
Net Income (TTM)163.06M $
Revenue/Share5.910 USD
Last Price8.200 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees191
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS21900C3088
Valuation
P/E (Trailing)3.76
P/E (Forward)23.51
PEG—
EV/EBITDA2.03
EV/Revenue1.15
P/S1.39
P/B1.48
EPS (TTM)2.11
EPS (Forward)0.35
52W Range
6.13023% of range14.96
52W High14.96 USD
52W Low6.130 USD
Profitability
Gross Margin88.46%
Oper. Margin42.10%
EBITDA Margin56.80%
Profit Margin52.31%
ROE40.23%
ROA19.74%
Growth
Revenue Growth156.50%
Earnings Growth6.70%
Cash Flow & Leverage
Operating CF175.05M $
CapEx (TTM)2.26M $
FCF Margin38.54%
FCF Yield27.87%
Net Debt-109.24M $
Net Debt/EBITDA-0.42
Balance Sheet
Debt/Equity0.37
Current Ratio2.56
Quick Ratio2.23
Book Value/Sh5.575 USD
Cash/Share3.293 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateMar 26, 2019
Splits
Last Split1:5
Split DateMar 26, 2019
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)15.40 USD
Upside (mean)+87.8%
Target Range13.00 USD – 19.00 USD
$13.00+87.8% to mean$19.00
# Analysts5
Ownership
Shares Out.77.94M
Float66.02M
Insiders7.58%
Institutions58.07%
Short Interest
Short Ratio17.0d
Short % Float21.03%
Short % Out.20.76%
Shares Short16.28M
Short (prev mo.)14.93M
Technical
SMA 508.101 (+1.2%)
SMA 2008.403 (-2.4%)
Beta1.50
S&P 52W Chg18.16%
Avg Vol (30d)1.20M
Avg Vol (10d)1.96M
Technical Indicators
RSI (14)54.8
MACD-0.0247
MACD Signal-0.1398
MACD Hist.+0.1151
BB Upper8.375 USD
BB Middle7.647 USD
BB Lower6.919 USD
BB Width19.04%
ATR (14)0.4819 USD
Vol Ratio (20d)1.09x